Sarah E. Yentz, MD1, Todd M. Morgan, MD2, Zachery R. Reichert, MD1

All articles by Sarah E. Yentz, MD1, Todd M. Morgan, MD2, Zachery R. Reichert, MD1

The development of BRCA-targeted therapies might offer the best opportunities to bring pancreatic ca

Prostate Cancer

The Potential Role for PARP Inhibitors in Prostate Cancer

By

Sarah E. Yentz, MD1, Todd M. Morgan, MD2, Zachery R. Reichert, MD1

August 10, 2018

Identification of DNA repair defects within prostate cancer tissue may enable a precision oncologic approach to treatment.

Next post in Prostate Cancer

G_radiotherapy_man

Use of Post-RP High Dose Radiotherapy Increasing